Treatment for Lifting Upper Arm Lax Skin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-01

Study Completion Date

2023-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Sofwave Treatment to Lift Lax Skin

NCT04829227

Skin Laxity

COMPLETED PHASE3

Combined Treatment Sofwave and Pure Impact to Strength and Tone Muscles and Improve Lax Skin Appearance

NCT06724146

Skin Lax and Muscle Strength

ACTIVE_NOT_RECRUITING NA

SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow

NCT04969380

Skin Laxity

COMPLETED NA

Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators

NCT06333067

Lax Skin

RECRUITING NA

Treatment for Improvement of Cellulite Appearance Using Form Applicator

NCT05882721

Cellulite

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients will receive 2 treatments on both upper arms (4-6 weeks apart) using the Sofwave System.

Treatment may be administered after the enrollment and screening at the first visit, or it may occur later following the enrollment and screening activities based on site scheduling availabilities. All patients will return to the clinic for follow up visit at 3 months ± 2 weeks post last treatment (FU1).

Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lax Skin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Upper Arm

Group Type EXPERIMENTAL

Sofwave

Intervention Type DEVICE

The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sofwave

The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SUPERB

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects \> 35 years of age and \< 70 years of age.
2. Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
3. Desire to undergo upper arms skin lax lifting treatments.
4. Subject has clearly visible lax skin on the upper arm, which in the investigator's opinion, may benefit from the treatment.
5. Subject agrees to maintain his/her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the course of the study.
6. Able and willing to comply with all visits, treatments and evaluations schedules and requirements.
7. Willing to have research photos taken of treatment areas.
8. Subject agrees not to undergo any other upper arm skin lax treatments for a period of 3 months following Sofwave treatment.
9. Able to understand and provide written Informed Consent.

Exclusion Criteria

1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
2. Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area.
3. Medical disorder that would hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.).
4. History of Epileptic seizures.
5. Known allergy to lidocaine or epinephrine or antibiotics.
6. Active malignancy or history of malignancy in the past 5 years.
7. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process).
8. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
9. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen.
10. History of significant lymphatic drainage problems.
11. Currently heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years.
12. History of chronic drug or alcohol abuse.
13. History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
14. Currently taking or has taken diet pills or weight control supplements within the past month.
15. BMI\>=30kg/m2
16. Non-stable weight nominally ±5% for at the past month.
17. Active implanted device such as a pacemaker, defibrillator, or drug delivery system.
18. History of epidermal or dermal disorders (particularly involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
19. History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.).
20. History of prior surgery in the upper arms.
21. Excessive subcutaneous fat on the upper arms.
22. Severe solar elastosis on the intended to treat area.
23. Significant scarring, atrophic scars in the area to be treated, or has a history of atrophic scars or keloids or prone to bruising.
24. Tattoo or former tattoo at or near treatment area.
25. Presence of an implant in or adjacent to area of intended treatment (upper arms).
26. History of ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep peeling within the past 12 months on the intended to treat area.
27. Inability to understand the protocol or to give informed consent.
28. On-going use of psychiatric medication.
29. Unable or unwilling to comply with the study requirements and procedures.
30. Currently enrolled in a clinical study of any other unapproved investigational drug or device.
31. Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Minimum Eligible Age

35 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes